Carotid artery

Life Line Screening Announces Launch of New Participant Results Platform

Retrieved on: 
Monday, March 27, 2023
Technology, Hospitals, Health Technology, Telemedicine, Virtual Medicine, Health Insurance, Software, Other Health, Managed Care, Health, Stroke, Growth, CBP Office of Field Operations, Liver, Glycated hemoglobin, Longevity, Education, Risk, History, Life Line Screening, Carotid artery, Mobile phone

Life Line Screening, the nation’s leading local community preventive health screening company focused on vascular health and the risk of stroke announced today the launch of their new My Life Line participant results technology platform.

Key Points: 
  • Life Line Screening, the nation’s leading local community preventive health screening company focused on vascular health and the risk of stroke announced today the launch of their new My Life Line participant results technology platform.
  • Life Line Screening’s CEO Matt Miller stated, “Life Line Screening is at an exciting time of growth and innovation as we focus on implementing technologies and service enhancements to provide the highest level of support and care to every customer.
  • “Investing in technology is another step towards ensuring Life Line Screening’s customers receive a superior overall experience.”
    Life Line Screening is the nation’s leading preventive health screening platform.
  • Life Line Screening takes a localized community-based approach to provide health screenings to over 50,000 customers per month, employing approximately 1,000 care providers.

InspireMD Announces Warrants Exchange Listing Transfer to Nasdaq

Retrieved on: 
Thursday, May 27, 2021
Medical specialties, Angiology, Vascular diseases, Cardiovascular system, Neurosurgery, Vascular surgery, Carotid artery stenosis, Carotid stenting, Stroke, Carotid artery, NASDAQ

TEL AVIV, Israel, May 27, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced the Companys warrants, NSPR.WS and NSPR.WSB, currently traded on the NYSE: American, have been approved for listing on The Nasdaq Capital Market (Nasdaq).

Key Points: 
  • TEL AVIV, Israel, May 27, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced the Companys warrants, NSPR.WS and NSPR.WSB, currently traded on the NYSE: American, have been approved for listing on The Nasdaq Capital Market (Nasdaq).
  • Trading is expected to begin onJune 8, 2021, under the symbols NSPRW and NSPRZ on the Nasdaq.
  • InspireMD seeks to utilize its proprietary MicroNet technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free, long-term outcomes.
  • Investors and security holders are urged to read these documents free of charge on the SECs web site at http://www.sec.gov.

InspireMD to Participate at the Investor Summit Conference and Present to Investors on May 17, 2021

Retrieved on: 
Friday, May 14, 2021
Medical specialties, Neurosurgery, Vascular surgery, Finance, Carotid artery stenosis, Carotid stenting, Clinical medicine, Stroke, Ticker symbol, New York Stock Exchange, Carotid artery

b'TEL AVIV, Israel, May 14, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR) developer of the CGuard\xe2\x84\xa2 Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), announced today that management will participate at the Investor Summit Conference on May 17, 2021.\nChief Executive Officer Marvin Slosman will deliver his corporate presentation at 11:00am ET on May 17, 2021.\nInvestors can also request a one-on-one meeting with Mr. Slosman to be arranged following the conclusion of the conference.\nInspireMD seeks to utilize its proprietary MicroNet\xc2\xae technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free, long-term outcomes.\nInspireMD\xe2\x80\x99s common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants are quoted on the NYSE American under the ticker symbol NSPR.WS and NSPR.WSB.\n'

Key Points: 
  • b'TEL AVIV, Israel, May 14, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR) developer of the CGuard\xe2\x84\xa2 Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), announced today that management will participate at the Investor Summit Conference on May 17, 2021.\nChief Executive Officer Marvin Slosman will deliver his corporate presentation at 11:00am ET on May 17, 2021.\nInvestors can also request a one-on-one meeting with Mr. Slosman to be arranged following the conclusion of the conference.\nInspireMD seeks to utilize its proprietary MicroNet\xc2\xae technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free, long-term outcomes.\nInspireMD\xe2\x80\x99s common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants are quoted on the NYSE American under the ticker symbol NSPR.WS and NSPR.WSB.\n'

InspireMD Announces Stock Exchange Listing Transfer to Nasdaq

Retrieved on: 
Monday, May 10, 2021
Carotid artery stenosis, Carotid artery, Stroke

b'TEL AVIV, Israel, May 10, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard\xe2\x84\xa2 Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced the Company\xe2\x80\x99s shares have been approved for listing on The Nasdaq Capital Market (\xe2\x80\x9cNasdaq\xe2\x80\x9d).

Key Points: 
  • b'TEL AVIV, Israel, May 10, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard\xe2\x84\xa2 Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced the Company\xe2\x80\x99s shares have been approved for listing on The Nasdaq Capital Market (\xe2\x80\x9cNasdaq\xe2\x80\x9d).
  • InspireMD is a stronger company today than ever before, and I am proud of the extraordinary efforts of our expanding team in creating an exciting future for our company.
  • Investors and security holders are urged to read these documents free of charge on the SEC\xe2\x80\x99s web site at http://www.sec.gov.
  • The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.\n'

InspireMD to Participate at the Benzinga Global Small Cap Conference and Present to Investors on May 14, 2021

Retrieved on: 
Thursday, May 6, 2021
Medical specialties, Neurosurgery, Vascular surgery, Carotid artery stenosis, Carotid stenting, Clinical medicine, Medicine, Stroke, Carotid artery

b'TEL AVIV, Israel, May 06, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR) developer of the CGuard\xe2\x84\xa2 Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), announced today that management will participate at the Benzinga Global Small Cap Conference on May 14, 2021.\nChief Executive Officer Marvin Slosman will deliver his corporate presentation at 11:10am ET on May 14, 2021.\nInvestors can also request a one-on-one meeting with Mr. Slosman to be arranged following the conclusion of the conference.\nInvestors can register for the conference here:\nInspireMD seeks to utilize its proprietary MicroNet\xc2\xae technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free, long-term outcomes.\nInspireMD\xe2\x80\x99s common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants are quoted on the NYSE American under the ticker symbol NSPR.WS and NSPR.WSB.\n'

Key Points: 
  • b'TEL AVIV, Israel, May 06, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR) developer of the CGuard\xe2\x84\xa2 Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), announced today that management will participate at the Benzinga Global Small Cap Conference on May 14, 2021.\nChief Executive Officer Marvin Slosman will deliver his corporate presentation at 11:10am ET on May 14, 2021.\nInvestors can also request a one-on-one meeting with Mr. Slosman to be arranged following the conclusion of the conference.\nInvestors can register for the conference here:\nInspireMD seeks to utilize its proprietary MicroNet\xc2\xae technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free, long-term outcomes.\nInspireMD\xe2\x80\x99s common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants are quoted on the NYSE American under the ticker symbol NSPR.WS and NSPR.WSB.\n'

InspireMD Provides Corporate Update for Shareholders

Retrieved on: 
Monday, April 19, 2021
Medical specialties, Neurosurgery, Vascular surgery, Vascular diseases, Carotid stenting, Clinical medicine, Carotid artery, Medicine

Our business model, superior technology platform harnessed by our proprietary MicroNet embolic protection system and timing of the growth in carotid stenting have laid the foundation necessary for CGuard EPS to become a market leader in the prevention of stroke caused by carotid artery disease.

Key Points: 
  • Our business model, superior technology platform harnessed by our proprietary MicroNet embolic protection system and timing of the growth in carotid stenting have laid the foundation necessary for CGuard EPS to become a market leader in the prevention of stroke caused by carotid artery disease.
  • We believe that moving to the Nasdaq Capital Market is a strategically sound approach that places us in the company of our peers and allows for improved visibility in the market.
  • Investors and security holders are urged to read these documents free of charge on the SEC\xe2\x80\x99s web site at http://www.sec.gov.
  • The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.\n'

InspireMD Engages Hart Clinical Consultants to Conduct Clinical Trial for CGuard Carotid Stent System in the United States

Retrieved on: 
Wednesday, February 24, 2021
Medical specialties, Angiology, Cardiovascular system, Neurosurgery, Vascular surgery, Vascular diseases, Carotid stenting, Carotid artery stenosis, Stroke, Carotid artery, Carotid endarterectomy

TEL AVIV, Israel, Feb. 24, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, announced today that it has engaged Hart Clinical Consultants (HCC), a leading Contract Research Organization (CRO) to conduct the clinical trial for its CGuard Carotid Stent System in the United States.

Key Points: 
  • TEL AVIV, Israel, Feb. 24, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, announced today that it has engaged Hart Clinical Consultants (HCC), a leading Contract Research Organization (CRO) to conduct the clinical trial for its CGuard Carotid Stent System in the United States.
  • HCC is ideally suited to manage this trial having supported clinical trial operations for a variety of products and indications, including with multiple carotid intervention procedures, stated Marvin Slosman, InspireMDs CEO.
  • This will be the first U.S.-based study of CGuard and our opportunity to demonstrate its potential for the prevention of stroke caused by carotid artery disease in patients in the United States.
  • We look forward to working with InspireMD on this pivotal trial of the CGuard System to help establish a new standard of care for the management of carotid artery disease and stroke prevention.

CVR Medical Corp. Message from the Chief Executive Officer

Retrieved on: 
Tuesday, February 9, 2021
Gross pathology, Medical terminology, Stenosis, Carotid artery

Vancouver, British Columbia--(Newsfile Corp. - February 9, 2021) - CVR Medical Corp. (TSXV: CVM) (OTC: CRRVF) ("CVR Medical" or the "Company" or "we") a Canadian listed and US based healthcare company in the medical device market is pleased to share an update from new Chief Executive Officer (CEO) Michael Rhodes:

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - February 9, 2021) - CVR Medical Corp. (TSXV: CVM) (OTC: CRRVF) ("CVR Medical" or the "Company" or "we") a Canadian listed and US based healthcare company in the medical device market is pleased to share an update from new Chief Executive Officer (CEO) Michael Rhodes:
    The Board of Directors is continuing to make progress on the terms of a restructuring agreement with input and guidance from me and Harvey McKenzie.
  • A key element of the restructuring agreement is to ensure CVR Medical has total and unincumbered ownership of all intellectual property.
  • Giving us the freedom to apply the non-emitting, non-invasive science and solutions behind the Carotid Stenotic Scan (CSS) to applications beyond the carotid artery.
  • CVR Medical Corp. is a healthcare company that operates in the medical device industry focused on the commercialization of its disruptive, proprietary Carotid Stenotic Scan device ("CSS").

InspireMD Secures Partner for Intended Registration and Distribution of CGuard EPS in Mainland China

Retrieved on: 
Wednesday, February 3, 2021
Vascular diseases, Carotid artery, Stroke

TEL AVIV, Israel, Feb. 03, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of the stroke caused by carotid artery disease, today announced a transaction intended to achieve distribution of CGuard EPS in mainland China.

Key Points: 
  • TEL AVIV, Israel, Feb. 03, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of the stroke caused by carotid artery disease, today announced a transaction intended to achieve distribution of CGuard EPS in mainland China.
  • Following announcement of the transaction the Chinese partners plan to initiate the process of securing registration with Chinese regulatory authorities to establish distribution.
  • One of our pillars of growth is global expansion of CGuard EPS into significant markets of opportunity and this step in China establishes a foundation for our overall Asia plan.
  • Investors and security holders are urged to read these documents free of charge on the SECs web site at http://www.sec.gov.

InspireMD, Inc. Appoints Patrick Jamnik as Vice President of Business Development and Strategic Initiatives and Reports Inducement Grants Under NYSE American Company Guide §711(a)

Retrieved on: 
Tuesday, October 6, 2020
Neurosurgery, Vascular surgery, Carotid stenting, Jamnik, Carotid artery

CGuard EPS presents the opportunity to create such an impact on the advancement of carotid artery stenting, said Mr. Jamnik.

Key Points: 
  • CGuard EPS presents the opportunity to create such an impact on the advancement of carotid artery stenting, said Mr. Jamnik.
  • Mr. Jamnik brings with him more than 15 years of global market development experience in broad-based roles with both large and emerging medical technology companies.
  • Investors and security holders are urged to read these documents free of charge on the SECs web site at http://www.sec.gov.
  • The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.